Dr. Steidl and Scott teams have successfully won a large-scale applied research project grant worth $11.9 million funded by Genome Canada, Genome BC, Canadian Institutes of Health Research and BC Cancer Foundation to study the genome biology of relapsed lymphoid cancers. Our large-scale, pan-Canadian study was launched to discover novel, actionable markers of relapsed lymphoma from which clinically relevant assays can be developed. This study also aims to implement genomic-based clinical assays, which have been previously developed by our research team, in the publicly funded health care system across the country to enhance more patient -centric approaches and improve outcomes for lymphoma patients.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.